These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 6751300)

  • 1. [Treatment of bile duct diseases. Dyskinesias. Chronic inflammation].
    Pontes JF; Tacla M
    Arq Gastroenterol; 1981; 18(4):156-61. PubMed ID: 6751300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Imecromone: a new choleretic with antispastic action on Oddi's sphincter. Clinical pharmacology and clinico-statistical study].
    Cremoncini C; Tominz L
    Minerva Med; 1968 Oct; 59(82):4359-68. PubMed ID: 5683717
    [No Abstract]   [Full Text] [Related]  

  • 3. [Use of cholagogic agents in the therapy of patients with dysfunction of the bile-secreting system].
    Nogaller AM; Barkhanova AG; Zakharova GIu
    Klin Med (Mosk); 1989 Sep; 67(9):129-35. PubMed ID: 2685457
    [No Abstract]   [Full Text] [Related]  

  • 4. [Controlled double-blind clinical study of cinnametic acid, a new choleretic agent in hepatobiliary diseases].
    Marchettini G; Maggi P; Benvenuti C
    Clin Ter; 1978 Sep; 86(5):485-94. PubMed ID: 367683
    [No Abstract]   [Full Text] [Related]  

  • 5. [Cholelithin therapy of angiocholecystites and dyskinesias of bile ducts in children].
    Shmorgun SS; Cherniavskaia VG
    Pediatr Akus Ginekol; 1967; 2():27-9. PubMed ID: 5610524
    [No Abstract]   [Full Text] [Related]  

  • 6. [Clinical studies on the effects of (3-chlor-pyridazinyl-6-thio)-acetic acid diethylamide (Oragallin)].
    Miyoshi A; Ito M; Nakanishi S; Hajiro T; Takeda T
    Naika Hokan; 1968 Mar; 15(3):77-82. PubMed ID: 5691521
    [No Abstract]   [Full Text] [Related]  

  • 7. [Significance of biliary dysfunction in the pathogenesis of gallstone disease].
    Il'chenko IA; Deliukina OV
    Eksp Klin Gastroenterol; 2011; (7):70-8. PubMed ID: 22364003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Action on the extrahepatic bile ducts of a choleretic compound: imechromone].
    Grossi F; Spada S
    Clin Ter; 1969 Oct; 51(1):41-7. PubMed ID: 5364032
    [No Abstract]   [Full Text] [Related]  

  • 9. [Effect of physical exercise during drug therapy of chronic cholecystoangiocholitis (clinicophysiological study)].
    Ragimov DM
    Vopr Kurortol Fizioter Lech Fiz Kult; 1970; 35(6):518-21. PubMed ID: 5515370
    [No Abstract]   [Full Text] [Related]  

  • 10. [Oragallin purum, a new choleretic].
    Dierel HL
    Wien Med Wochenschr; 1965 Jul; 115(30):613-5. PubMed ID: 5319876
    [No Abstract]   [Full Text] [Related]  

  • 11. Ursodeoxycholic acid reduces lipid peroxidation and mucin secretagogue activity in gallbladder bile of patients with cholesterol gallstones.
    Jüngst C; Sreejayan N; Zündt B; Müller I; Spelsberg FW; Hüttl TP; Kullak-Ublick GA; del Pozo R; Jüngst D; von Ritter C
    Eur J Clin Invest; 2008 Sep; 38(9):634-9. PubMed ID: 18837739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The condition of the biliary tract and cholesecretion in cases of ulcerative colitis.
    Abasov IT; Isaev EG; Iof IM
    Hepatogastroenterology; 1985 Jun; 32(3):138-40. PubMed ID: 4018708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cholagoga and choleretics; for the therapy of gallbladder and biliary tract diseases].
    VOLLENWEIDER H
    Suddeutsch Apoth Ztg; 1948 Sep; 88(10):262-5. PubMed ID: 18894910
    [No Abstract]   [Full Text] [Related]  

  • 14. Increase of deoxycholate in supersaturated bile of patients with cholesterol gallstone disease and its correlation with de novo syntheses of cholesterol and bile acids in liver, gallbladder emptying, and small intestinal transit.
    Shoda J; He BF; Tanaka N; Matsuzaki Y; Osuga T; Yamamori S; Miyazaki H; Sjövall J
    Hepatology; 1995 May; 21(5):1291-302. PubMed ID: 7737634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The relationship between Oddi's sphincter and bile duct pigment gallstone].
    Wu SD; Yu H; Wang HL; Su Y; Zhang ZH; Sun SL; Kong J; Tian Y; Tian Z; Wei Y; Jin HX; Jin JZ
    Zhonghua Wai Ke Za Zhi; 2007 Jan; 45(1):58-61. PubMed ID: 17403294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hepaticocholangiochole cystostomy plus construction of subcutaneous tunnel of the gallbladder in the treatment of hepatolithiasis with bile duct stricture].
    Tian F; Zhao T; Hu J
    Zhonghua Wai Ke Za Zhi; 1997 Jan; 35(1):28-30. PubMed ID: 10374503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abnormal duodenal bile composition in patients with acalculous chronic cholecystitis.
    Venkataramani A; Strong RM; Anderson DS; Gilmore IT; Stokes K; Hofmann AF
    Am J Gastroenterol; 1998 Mar; 93(3):434-41. PubMed ID: 9517653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment.
    Stiehl A; Rudolph G; Sauer P; Theilmann L
    J Hepatol; 1995 Sep; 23(3):283-9. PubMed ID: 8550992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Xylitol as a choleretic and cholecystokinetic agent].
    Gruncharov V
    Vutr Boles; 1973; 12(2):69-73. PubMed ID: 4713058
    [No Abstract]   [Full Text] [Related]  

  • 20. [Galstena efficacy in patients with biliary dyskinesia, chronic cholecystitis and cholelithiasis].
    Grigor'eva IN; Shabalin AV; Tikhonov AV; Moiseenko EE; Ragino IuI
    Klin Med (Mosk); 2001; 79(11):52-4. PubMed ID: 11811112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.